Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
casirivimab + imdevimab
DRUG
2 trials
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
, Regeneron Pharmaceuticals
Conditions
Coronavirus
Covid19
SARS-CoV-2
Phase 1
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Terminated
NCT05081388
Regeneron Pharmaceuticals
SARS-CoV-2
Start: 2021-11-08
End: 2022-06-30
Updated: 2025-10-28
Phase 2
ACTIV-2: A Study for Outpatients With COVID-19
Completed
NCT04518410
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus, Covid19
Start: 2020-08-19
End: 2023-06-20
Updated: 2024-08-02
Related Papers
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19
UNC Libraries
2025-02-05
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
UNC Libraries
2025-02-05
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
UNC Libraries
2025-02-05
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial
UNC Libraries
2025-02-05
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
UNC Libraries
2025-02-05
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
UNC Libraries
2025-02-05
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
UNC Libraries
2024-10-03
Variant-Specific Viral Kinetics in Acute COVID-19
UNC Libraries
2024-09-01
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
UNC Libraries
2024-09-01
Immune Status and SARS-CoV-2 Viral Dynamics
UNC Libraries
2024-09-01
Long COVID After Bamlanivimab Treatment
UNC Libraries
2024-09-01
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
Pathogens and Immunity
2024-08-21
2 citations
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial
The Journal of Infectious Diseases
2024-07-18
1 citations
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19
Clinical Infectious Diseases
2024-07-17
2 citations
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
UNC Libraries
2023-10-11
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
2023-10-06
9 citations
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
2023-10-01
14 citations
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients
The Journal of Infectious Diseases
2023-08-31
12 citations
Immune Status and SARS-CoV-2 Viral Dynamics
The Journal of Infectious Diseases
2023-08-31
12 citations
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
The Journal of Infectious Diseases
2023-08-31
8 citations
17 more papers not shown